People on CGRP-blocking migraine drugs reported less depression and less anxiety, measured across six standard rating scales. The catch is that almost none of those measurements came from a placebo-controlled trial, and the single comparison that had a placebo group came up empty.
That is the read from a systematic review and meta-analysis ↗ published September 12 in Cephalalgia by a team at the Danish Headache Center in Copenhagen, joined by Richard Lipton of the Albert Einstein College of Medicine in New York. They pooled twelve studies covering 3,603 adults with migraine, most of them women, published between 2020 and 2026. Nine of the twelve fed numbers into the pooled statistics.
Migraine is a CGRP disease. Calcitonin gene-related peptide is a short signaling molecule that nerve cells release to widen blood vessels and carry pain signals, and the newest preventive drugs work by mopping it up or blocking the receptor it docks into. Alpha-CGRP ↗ is the human form of that peptide. The injected antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the oral gepants all point at the same CGRP-receptor axis ↗. Depression and anxiety ride along with migraine often enough that the question is fair. If you turn the peptide down, does the mood lift too?
The numbers all leaned the same way
On the pooled scores, every instrument moved toward improvement at three months. Depression fell by 1.35 points on the Hospital Anxiety and Depression Scale (95 percent confidence interval 1.07 to 1.63), by 3.73 points on the Hamilton Depression Rating Scale, and by 3.70 points on the Beck Depression Inventory. Anxiety followed: down 1.50 points on the Hospital Anxiety and Depression Scale, 1.64 on the Hamilton Anxiety scale, and 4.36 on the Beck Anxiety Inventory.
In plain terms, these are small to moderate drops on scales where a higher number means worse symptoms. A 1.35-point fall on a scale that runs 0 to 21 is modest but real, and the fact that six different questionnaires all pointed the same way is the part that looks convincing.
The one controlled test found nothing
Then the design problem. Most of the pooled studies were single-arm, measuring the same patients before and after starting the drug, or observational cohorts with no comparison group. Only one placebo-controlled subgroup existed, built on fremanezumab, and there the drug was numerically better than placebo for depression but the difference did not reach statistical significance. The pile of improvement is almost entirely uncontrolled.
That matters because the authors also note the mood gains appear to track how well each drug controlled the migraine itself. Picture someone whose attacks drop from fifteen days a month to five. They feel better across the board, and a depression score falls with the headache count. That is not the same as the peptide acting on mood circuits directly. A before-and-after study cannot separate a direct effect on mood from the ordinary lift of simply having fewer migraine days, and neither can it rule out regression to the mean or the placebo response that shadows any open-label treatment.
Why the gap is the story
Migraine and depression feed each other, and a preventive drug that treated both at once would change how neurologists prescribe. But "associated with lower scores in uncontrolled studies" is exactly the signature that expectancy and regression to the mean throw off. The honest conclusion is the one the authors reach: the association is consistent, the causal claim is not established, and it will take trials that are built to measure psychiatric symptoms as a planned endpoint, with a placebo arm, to say whether blocking CGRP lifts mood or just clears the headaches that were dragging it down.
There is a pattern here worth remembering. When CGRP antibodies were tested head to head against placebo in cluster headache rather than migraine, they barely beat the placebo ↗. The controlled comparison is where CGRP effects tend to shrink. This mood analysis is a large, careful reminder to wait for that comparison before believing the pile.